Vicore Pharma Holding AB (STU:6Y4) ROCE % : -55.31% (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Vicore Pharma Holding AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Vicore Pharma Holding AB's annualized ROCE % for the quarter that ended in Sep. 2024 was -55.31%.

Vicore Pharma Holding AB ROCE % Historical Data

The historical data trend for Vicore Pharma Holding AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vicore Pharma Holding AB ROCE % Chart

Vicore Pharma Holding AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-30.21

-43.77

-79.41

-82.03

-82.63

Vicore Pharma Holding AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-58.04	-90.36	26.55	-48.63	-55.31

Vicore Pharma Holding AB ROCE % Calculation

Vicore Pharma Holding AB's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-27.831	/	( ( (30.746 - 4.222)	+	(44.505 - 3.662) )	/ 2 )
	=	-27.831	/	( (26.524	+	40.843)	/ 2 )
	=	-27.831	/	33.6835
	=	-82.63 %

Vicore Pharma Holding AB's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-19.968	/	( ( (42.409 - 3.537)	+	(35.841 - 2.512) )	/ 2 )
	=	-19.968	/	( ( 38.872	+	33.329 )	/ 2 )
	=	-19.968	/	36.1005
	=	-55.31 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Vicore Pharma Holding AB (STU:6Y4) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Vicore Pharma Holding AB ROCE % Related Terms

Thank you for viewing the detailed overview of Vicore Pharma Holding AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Vicore Pharma Holding AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicore Pharma Holding AB (STU:6Y4) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

VICO:Sweden

Address

Kornhamnstorg 53, Stockholm, SWE, 111 27

Website

https://www.vicorepharma.com

Vicore Pharma Holding AB is as a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2a development for IPF. The company also has an investigational medical device in clinical development namely, Almee which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.

Vicore Pharma Holding AB Headlines

No Headlines